Neuropsychological Deficits in Mice Depleted of the Schizophrenia Susceptibility Gene CSMD1

Vidar M. Steen1,2, Chirag Nepal1,2, Kari M. Ersland1,2, Rita Holdhus1,2, Marianne Nævdal1,2, Siri M. Ratvik1,2, Silje Skrede1,2, Bjarte Håv1,2*

1 Dr E. Martens Research Group for Biological Psychiatry and K.G. Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, Bergen, Norway, 2 Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

Abstract

Recent meta-analyses of schizophrenia genome-wide association studies (GWASs) have identified the CUB and SUSHI multiple domains 1 (CSMD1) gene as a statistically strong risk factor. CSMD1 is a complement control-related protein suggested to inhibit the classical complement pathway, being expressed in developing neurons. However, expression of CSMD1 is largely uncharacterized and relevance for behavioral phenotypes is not previously demonstrated. Here, we assess neuropsychobehavioral characteristics of a Csmd1 knockout (KO) mouse in a selection of standard behavioral tests. Deregulation of neuropsychological responses were observed in both the open field and the elevated plus maze tests, in which KO mice spent 55% and 33% less time than WT littermate mice in open areas, respectively. Altered behaviors were also observed in tail suspension and to higher acoustic stimuli, for which Csmd1 KO mice showed helplessness and moderate increase in startle amplitude, respectively. Furthermore, Csmd1 KO mice also displayed increased weight-gain and glucose tolerance, similar to a major phenotype of the metabolic syndrome that also has been associated to the human CSMD1 locus. Consistent with a role in the control of behaviors, Csmd1 was found highly expressed in the central nervous system (CNS), and with some expression in visceral fat and ovary, under tissue-specific control by a novel promoter-associated lncRNA. In summary, disruption of Csmd1 induces behaviors reminiscent of blunted emotional responses, anxiety and depression. These observations suggest an influence of the CSMD1 schizophrenia susceptibility gene on psychopathology and endophenotypes of the negative symptom spectra.

Introduction

Schizophrenia is a severe psychiatric disorder of high heritability with a lifetime risk of approximately 1%. Onset of symptoms typically occurs in young adulthood, with chronic deregulation of behavior and emotions, including psychotic symptoms (hallucinations and delusions), emotional flattening and cognitive dysfunctions. Affective symptoms and anxiety are also regarded as key findings in this complex disorder [1]. The etiology of schizophrenia is thought to have a neurodevelopmental basis that disrupts neuronal plasticity and transmission, but the identification of disease mechanisms has proven difficult, not least due to the phenotypic heterogeneity and polygenic contributions. Still, alterations in immunity-related processes in schizophrenia have been documented in both epidemiological and genetic studies conducted over the past decades [2,3]. While it is clear that complex genetic and environmental factors contribute to disease risk [4], the effect of specific immune-related genes on neuropsychological behaviors remains to be elucidated.

We previously found that the activity of complement-related factors (including complement component C3) was induced during long-term potentiation (LTP) of synaptic strength in the hippocampus of awake rats – a mechanistic model of learning and memory [5]. Since dysfunction in synaptic activity and cognitive abilities has been recognized as a primary and enduring core deficit in schizophrenia, we examined a set of complement control-related genes as potential susceptibility factors in schizophrenia, and identified statistically strong genetic associations to the homologous genes CSMD1 and CSMD2, as well as to the CR1 locus (C3 receptors) [6]. In parallel, the Psychiatric Genome-Wide Association Study (GWAS) Consortium (PGC) identified CSMD1 as one of only seven verified loci in a large schizophrenia GWAS-based meta-analysis involving about 18,000 patients and 34,000 controls [7].

The CSMD1 gene encodes a complement control-related protein with multiple copies of CUB and Sushi, a single transmembrane domain and an intracellular signaling peptide. The function of the CSMD1 protein is sparsely described, but inhibition of complement C3 activation is demonstrated in vitro [8,9]. Although a possible relevance of CSMD1 has been reported in autoimmune disease (neonatal lupus) [10], the precise role of CSMD1 in immune responses remains to be further described. Distinct from a role in classic immunological pathways, it has also become clear that complement activity is tightly controlled in the brain, regulating C3/CR3-dependent axonal pruning by phago-

Copyright: © 2013 Steen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the Research Council of Norway (Psykisk Helse Grant No. 186001 and the FUGE Grant Nos. 151904 and 183327), Bergen Medical Research Foundation (BMFS), The Kristian Gerhard Jebsen Foundation, Helse Vest RHF and Dr. Einar Martens Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: bjarte.havvik@uib.no

Citation: Steen VM, Nepal C, Ersland KM, Holdhus R, Nævdal M, et al. (2013) Neuropsychological Deficits in Mice Depleted of the Schizophrenia Susceptibility Gene CSMD1. PLoS ONE 8(11): e79501. doi:10.1371/journal.pone.0079501
cycytic microglia. This mechanism ensures precise wiring of neuronal circuits in the visual system during development [11]. It is therefore believed that deregulation of complement could lead to aberrant synaptic elimination also in other parts of the brain, which may influence the risk of both neurodegenerative and psychiatric disorders [12].

Further suggesting a role of CSMD1 in psychopathology, GWAS studies on bipolar disorder (BIP) and major depressive disorder (MDD) also include nominal significant associations of genetic markers in CSMD1, which can be found in supplemental data in relevant literature [13–15]. BIP, MDD and schizophrenia are presently regarded as related disorders [4,16] with partial overlap of symptom spectra including emotional flattening, depressive features and anxiety. It is postulated that the etiology of related psychiatric disorders depends on heritable endophenotypes that partially penetrate across disease borders, as well as on genetic risk factors that are selective to a particular disease [17]. We have suggested that the complement control-related CSMD1 may affect shared symptomology in several psychiatric disorders [6]. However, the specific effect of complement factors on neuropsychological behavior is not known, and is very difficult to dissect in humans. We therefore sought to investigate the relevance of the CSMD1 expression on neuropsychological endophenotypes using gene knock out (KO) mice. In the current study, we describe a constitutive Csmd1 KO mice and determine the effect of Csmd1 expression on behaviors using a selection of classical neuropsychological tests.

Results

Constitutive Disruption of Csmd1 Expression in Mice

To investigate the functional relevance of Csmd1 in the regulation of neuropsychopathological behaviors, we used a constitutive gene deletion to disrupt Csmd1 gene expression in mice. The Reference Sequence collection describes mouse Csmd1 as a 1.65 Mb long and 72 exon-rich gene, which encodes a 14 kb mRNA. To block expression through a minimal transgenic manipulation, a constitutive knockout (KO) of a 1 kb sequence from Csmd1 exon1/intron1 was generated (Figure 1A). In WT mice, we found Csmd1 mRNA to be expressed in the central nervous system (CNS) with highest levels in the cortex, while expression in peripheral tissues was not observed except for low levels in visceral fat and ovary (Figure 1B). In the KO mice, depletion of Csmd1 mRNA and protein expression was documented by QPCR (exon1–2 junction-specific assay) and immunoblotting (custom-made goat anti-Csmd1 antibody) on cortex samples, respectively (Figure 1C). Consistent with disrupted Csmd1 expression (Figure 1C), the deleted genomic DNA region was shown to be the major site for Pol2 binding, and H3K4me1, H3K4me3 and H2K27Ac modified nucleosomes – physical features of core-promoter activity (Figure 1D) [18]. Exact and complete removal of the targeted genomic DNA sequence was confirmed by specific loss of RNA products complementary to the deleted DNA region, as shown by comparing RNA sequencing data of individual Csmd1 KO (n = 4) and WT (n = 4) mice to the mouse genomic reference sequence, respectively (Figure 1D).

The Csmd1 locus consists of 72 exons and several long intronic regions. In Csmd1 KO mice, some remaining transcription could be identified further downstream of the transcriptional start site (TSS) in exon 1, as documented by QPCR (exon 32–33 specific assay) (Figure 1C). We therefore examined how the exon1/intron1 deletion affected the transcription across the entire locus by analyzing the RNA sequencing data. We identified markedly reduced RNA transcription constitutive to all exons and introns of Csmd1 (Figure 2A). Both QPCR and RNA sequencing suggest at least 60–70% reduction in the expression of Csmd1 in the 3’ end of the gene, but we have not linked remaining expression to alternative Csmd1 transcripts.

To clarify that Csmd1 is the major deregulated genomic component of Csmd1 KO mice, we analyzed the RNA transcriptome sequences for differentially expressed genes: Csmd1 was the only significantly down-regulated gene in KO mice (Figure 2B). Overall, we observed a remarkably stable transcriptome profile, but noticed up-regulation of long non-coding RNAs (lncRNA) from two separate loci on chromosome 4 and 8 respectively (expression fold change KO/WT = 1.8–3.3; P-values<0.05) in the KO mice (Figure 2B, Table S1 in file S1). The identified lncRNAs are not functionally annotated in the literature. We also constructed and explored the expression profile of novel transcripts, finding only one Csmd1 promoter-associated (pas) long non-coding IncRNA to be differentially expressed (expression fold change KO/WT = 15±2.3; P-value<0.05) (Figure 3A). The pas-lncRNA is expressed antisense to the Csmd1 promoter and display co-regulated expression with Csmd1 specifically in the adult and developing CNS (Figure 3B and 3C). In contrast, in peripheral tissues (where Csmd1 mRNA expression levels are low) the expression of pas-lncRNA was constitutively high (Figure 3B). Thus, the expression of pas-lncRNA may reflect a mechanism for tight control of Csmd1 promoter-activity specifically in the CNS.

Behavioral Characterization of Csmd1 Knockout Mice

A preliminary screen of health status and fertility identified no major defects in the Csmd1 KO mice (see Materials and methods). However, preliminary examinations of the original repository Csmd1 KO model revealed possible neuropsychopa
dysfunctionalities (n = 4–8 mice/genotype) (Figure S1 in file S1). Although with borderline statistical significance and low numbers (n = 4–8), the KO genotype was associated with marked effects in the open field test (50% reduced time in the open center, P-value = 0.1; Figure S1A in file S1), the tail suspension test (56% increased immobility time, P-value = 0.1; Figure S1B in file S1) and in the response to acoustic stimuli (59% increased startle amplitude, P-value = 0.1; Figure S1C in file S1).

We therefore performed a comprehensive analysis of behaviors and assessed a larger number of homozygous Csmd1 KO and WT littermate mice, using a separate line of mice on a similar genetic background (n = 23–24 mice/genotype). Mice were generated in one breeding scheme using heterozygote female and heterozygote male mice (except for the EPM test). Testing of littermate offspring started at age 10 weeks. Non-stressful tests were conducted on the same set of animals with a one-week interval in the sequence considered most optimal (detailed in Materials and methods). We also recorded diurnal locomotor activity and metabolism for each animal, to control for underlying phenotypes that could interfere with the behavioral assessment in specific tests.

Csmd1 KO Mice Avoid Open Space in the Open Field and Elevated Plus Maze Tests

The effect of Csmd1 on the free adaption and exploration of a novel environment was first investigated by introducing the mice to the open filed (OF) arena: The time spent in the center of the field (open/exposed area) as opposed to a path along the borders (close to walls and corners) was recorded. Csmd1 KO mice spent 55% less time in the center (average time ± s.e.m: WT: 27±4.3 sec., KO: 12±2.1 sec.; genotype group P-value = 0.003), but travelled a similar total distance during the test period, as
compared to the WT mice (Figure 4A and 4C). Csmd1 KO and WT mice also displayed a marked difference in adaptation to the test arena following the initial exposure (first time bin) (Figure 4B and D): WT mice habituated to the OF center during the first period, and thereafter spent up to 80% more time exploring the center area. In contrast, Csmd1 KO mice gradually avoided the center and ended the test by spending 43% less time in the center (last vs. first time bin).

To replicate the effect of Csmd1 expression on the exploration of new and open arenas, we examined the behavior of a separate (but smaller) set of Csmd1 KO and WT littermate control mice in the elevated plus maze (EPM). In the EPM, mice are free to enter “closed” arms (corridors with high walls) or “open” arms (exposed platforms). While WT mice explored both corridors and platforms, Csmd1 KO mice spent 33% less time on the open platforms (average time on platform WT: 73±11, KO: 48±5.3;
genotype group P-value = 0.001) (Figure 5A) and stopped exploration (froze) just after crossing the entry point (Figure 5B). The marked avoidance of exploring the open platforms occurred despite Csmd1 KO and WT mice showing similar numbers of open platform entries (average “open” platform entries ± s.e.m = WT: 15±2.0, KO: 13±1.7; genotype group P-value = n.s.).

Deregulated Behaviors in Csmd1 KO Mice in Response to Acoustic Startle Stimuli and Tail Suspension Tests

Assessment of the acoustic startle reflex in mice has also been used to measure anxiety-like behaviors. Pre-pulse inhibition (PPI) of acoustic startle response may further indicate defects in the gating of neuronal signals and is often identified in candidate genes of psychotic disorders [19-21]. We therefore measured basal startle responses in Csmd1 KO and WT mice, finding a moderate, but significant elevation of startle amplitude to higher acoustic stimuli in Csmd1 KO mice (both genders combined; P-value = 0.043) (Figure 6A). Examination of PPI of the startling amplitude in Csmd1 depleted mice showed no impairment, as normalized to the basal startle reflex (Figure 6B).

The effect of Csmd1 on affect-like response was analyzed by the tail suspension test (TST), measuring the total time spent immobile. The test is classically used to investigate the effect of anti-depressant drugs and associates immobility with features of depression [learned helplessness] [22]. In suspended position, the Csmd1 KO mice spent 25% more time immobile as compared to WT littermates (both genders combined) (average time immobile ± s.e.m = WT: 144±11.3, KO: 181±11.2; genotype group P-value = 0.02) (Figure 6C). This finding may link Csmd1 expression to the state of learned helplessness.

Csmd1 KO Mice Display Increased Exploratory Activity but show Retained Memory in the Novel Object Recognition Test

The effect of Csmd1 was also assessed for the cognitive process of recognition memory, as we previously identified a possible role of complement control-related genes in LTP [5]. The preference and discrimination between novel and familiar objects was measured. Notably, the Csmd1 KO mice displayed a marked increase in exploratory activity to both familiar and novel objects, as compared to WT mice (2.4 fold increase, P-values<0.0001 in both 1st and 2nd trail; Figure 7A and B). The behavior of Csmd1 KO mice reflects frequent nose contacts, and not a mere effect of the time spent at each object. With respect to object recognition, the test displayed no difference in working memory, illustrated by similar preference and discrimination (D2) indexes between mice genotypes (Figure 7C and 7D). However, we cannot rule out interference as mediated by e.g. increased exploration or anxiety- and depression-like behaviors (as documented in Figures 4 and 6).

Increased Body Weight in Csmd1 KO Mice

After completing the assessment of behaviors in OF, NORT, PPI and TST, we examined the behavior of Csmd1 KO and WT mice outside the test arenas. The diurnal pattern of ambulatory, non-ambulatory (grooming), rearing, licking (drinking) and metabolic activities were measured in a Comprehensive Cage Monitoring System (CCMS) using non-invasive automated recordings.

The CCMS-based analyses revealed some genotype-specific activities in the dark-period only, but not of equal effect in both genders (Figure S2 in file S1). In the dark period, Csmd1 depletion increased the total horizontal activity counts in male mice (Figure S2A in file S1). The increase in activity was specific for ambulatory movements (68–76% increase, male-genotype group P-value = 0.004). In contrast, the total horizontal activity of female Csmd1 KO mice remained unaffected (Figure S2B in file S1), but with a small reduction in non-ambulatory movements in the dark periods only (28–52% decrease, female-genotype group P-value = 0.03).

Changes in diurnal activity were gender and dark period specific, and therefore not believed to interfere with neuropsychological behaviors observed in the standard tests. The standard tests were performed during defined times of the light periods and the effect of Csmd1 depletion on neuropsychological behaviors was identified in both genders.

We routinely monitored the weight of all animals during regular handling and when examining behaviors (water and food ad libitum). We identified a significant accumulation of body weight over time, especially in female mice (% average weight gain ± s.e.m after 18 weeks: male mice: 12.8±0.12, genotype group P-value = 0.01; female mice: 21.2±0.14, genotype group P-value = 0.01) [Figure S3A in file S1]. To gain further insight into the metabolic phenotype, we measured the effect of Csmd1 expression...
on glucose tolerance, finding increased glucose tolerance in Csmd1 KO mice as compared to WT mice (Figure S3B in file S1). CCMS-based measurements of metabolic rate (CO₂ production) did not differ between Csmd1 KO and WT mice (data not shown).

**Discussion**

In this study, we provide an important biological validation of the CSMD1 schizophrenia susceptibility gene by demonstrating that Csmd1 expression affects the deregulation of neuropsychological behaviors in mice, thereby showing a potential functional relevance of this gene locus in psychopathology. Using a transgenic mouse line depleted of Csmd1 expression, we demonstrate that Csmd1 is primarily expressed in the brain (Figure 1), and that loss of expression induces agoraphobic-like responses in the open field and elevated plus maze apparatuses, as well as a blunted response (learned helplessness) upon tail suspension (Figures 4, 5 and 6). These tests are classically used to measure the effect of substances developed for the treatment of anxiety and depression [22,23]. Although it may be difficult to pinpoint the precise human phenotypic counterparts, the behavioral assessment of Csmd1 KO mice could be relevant for endophenotypes of complex psychiatric conditions, including parts of the negative and affective responses of schizophrenia which significantly contribute to impaired quality of life in these patients [1,24].

The observation of anxiety- and depression-like behaviors in Csmd1 KO mice may also provide one example supporting the notion of shared genetic susceptibility across schizophrenia, bipolar disorders and major depression [16]. These are heritable...
and related disorders with partial overlap of symptom spectra including emotional flattening, depressive features and anxiety. Genetic associations to CSMD1 can be found in all three disorders (as found among association data reported in supplemental information of [13–15]).

The relevance of Csmd1 for brain functions was further emphasized by the identification of a Csmd1 promoter-associated IncRNA, possibly responsible for brain-specific promoter activity in the adult and developing CNS (Figure 3). Such promoter-associated IncRNAs is a new class of long untranslated RNA which may underlie a functional coupling of transcription and translation/splicing [25,26]. Finally, we also demonstrate that depletion of Csmd1 has a remarkably limited effect on the whole transcriptome (Figure 2). Together, these findings suggest a key role of Csmd1 itself on the control of neuropsychological behaviors and provide a new framework for understanding how CSMD1 misexpression may lead to onset of neuropsychiatric disorders.

When assessing the memory performance of KO mice, we observed no effect of Csmd1 expression on object discrimination of preference. However, we did observe a large and highly significant increased exploration of objects (both familiar and new) in Csmd1 KO mice (Figure 7). Retained memory performance may seem unexpected, since we have previously linked the expression of complement control-related genes to LTP [5]. However, we cannot rule out that increased object contacts (exploration) are due to the observed agoraphobia-like behavior of Csmd1 KO mice, which leads to avoidance of open space and, therefore, might mask possible defects in object preference in the KO mice.

Recently, a similar Csmd1 KO introduced on a mixed B6:129 (B6 strain unknown) mouse genetic background was observed for changes with respect to behaviors of social interaction, anhedonia, pre-pulse inhibition (PPI) of startle reflex and locomotor response to d-amphetamine [27]. These behaviors are often related to complex schizophrenia-like behaviors, but the study did not find any behavioral changes in Csmd1 KO mice. PPI is the only test overlapping with our report, and we both find no genotypic effects. However, considering the possible association of human CSMD1 with depression and anxiety-linked disorders with suspected genetic overlap to schizophrenia (see introduction), we tested relevant behaviors in Csmd1 KO mice in response to basic startle response, open field, elevated plus maze and tail suspension. Although we assess different behavioral test than Distler et al., positive findings may also be influences by additional factors: The mice used in the two studies are derived and maintained on separate mouse strains. While we used RNA sequencing to confirm genomic depletion and mechanisms of CNS-specific expression, residual expression and KO of the Csmd1 DNA segment is not characterized by genomic analyses by Distler et al. Also, we use a higher number of mice and analyze possible gender-mediated difference in behaviors. Analyzing high number of mice may be essential to compensate for increased behavioral variance that may be linked to heterozygous breeding patterns on mixed genetic backgrounds.

Furthermore, anxiety- and depression-like behaviors, i.e. phenotypes we identified in Csmd1 KO mice, may mask the effects of the Csmd1 KO in complex context-dependent tests like e.g. social learning. Also, we control for diurnal activity pattern of each mouse in our study, and therefore applied single housed mice prior to testing. Housing conditions may trigger some of the underlying susceptibility for neuropsychological deficits in Csmd1 KO mice. Social isolation in both young and adult mice has in recent reports been demonstrated to be a relevant stressor generating deficits in the function of neuronal circuits and behaviors [28,29]. The ability of Csmd1 KO mice to capture the influence of environment (stresses) x gene interactions is to be examined in future studies.

The Csmd1 KO mouse captures several major clinical phenotypes that have been associated to the human CSMD1 locus, both psychiatric disorders and somatic conditions. The presence of weight gain and altered glucose tolerance in Csmd1 KO mice is consistent with the strong association of CSMD1 to the body-mass-index and measures of the metabolic syndrome in the large Framingham Heart Study [30]. This observation provides an important cue to further examine the effect of Csmd1 on metabolism as part of a complex biological system [31,32]. Metabolic disturbances are of major relevance for schizophrenia-
spectrum disorders, and some studies have identified severe metabolic deregulations in patients [33–35]. However, it is still not fully understood how central and peripheral signaling pathways in combination with antipsychotic treatment and genetic susceptibility provoke such clinical symptoms [36]. A detailed analysis of possible CNS and peripheral tissue mechanisms responsible for the metabolic phenotype of \(\text{Csmd1}\) KO mice is to be explored in future studies.

An unresolved question is which molecular and cellular mechanisms mediate the influence of \(\text{Csmd1}\) on psychiatry-relevant behaviors. A prominent molecular feature of CSMD1 is the extracellular repeated pattern of CUB and Sushi, domains primarily found in complement- and development-related proteins [37,38]. Many of these proteins assist, or “complement”, the process of clearing pathogens for destruction by other cells, as part of the innate immune system. In the peripheral immune system, the complement cascade is activated through the classical, alternative, or lectin pathways, all converging on the activation of complement C3 leading to the formation of the membrane attack complex [39]. Recombinant CSMD1 is reported to block complement C3 activation and cell clearance [8].

It has become increasingly clear that immune molecules, in addition to their roles in classical immunological pathways, contribute to brain development and function [40,41]. Complement components are localized to developing synapses where they play an essential role for synaptic refinement and precise neuronal connectivity, and mice deficient in the classical complement cascade (C1q, C3 KO) exhibit similar defects in synaptic pruning in the developing brain [42,43]. In the brain, complement factors (C3, CR3) mediate microglia-synapse interaction and regulate activity-dependent synaptic pruning in the postnatal reiniguliculate system [11], implicating a key role of complement in protecting synapses from aberrant elimination. In the adult brain, we have demonstrated expression of similar molecules (complement and HLA) during hippocampal LTP [5].

Our identification of predominant expression of \(\text{Csmd1}\) in adult brain may therefore indicate a relevance of the complement pathway in neuronal processes underlying the risk of schizophrenia, and may contribute to further insight into the suspected link between immunological factors and disease risk in psychiatric disorders.

**Materials and Methods**

These experiments were approved by the Norwegian Committee for Animal Research in accordance with European Community Council Directives.

**Csmd1 Knockout Mice**

A DNA sequence-verified repository \(\text{Csmd1}\) gene knock-out (KO) mouse model (clone TF0137, Taconic, Denmark) was generated with embryonic stem cells derived from 129SvEvBrd mice, in which a 1,070 bp genomic sequences of the exon 1-intron 1 junction was replaced with a LacZ/Neo selection cassette [44]. The selection cassette is expressed in frame with the starting protein-coding sequence of \(\text{Csmd1}\) in exon 1. In the present study,

---

**Figure 6. Behavior of \(\text{Csmd1}\) KO and WT mice to acoustic stimuli and tail suspension.** (A) Startle responses of \(\text{Csmd1}\) KO mice in response to acoustic stimuli in the range of 80–120 dB, as compared to WT mice. The startle baseline was similar in male and female WT mice. A marginal increase in startle responses could be observed for higher acoustic stimuli in both genders of \(\text{Csmd1}\) KO mice, reaching statistical significance when analyzing all mice together (genotype-group interaction \(P\)-value <0.05). (B) There was no difference in amplitude response between KO and WT mice in the degree of inhibition after pre-pulse inhibition. (C) Tail suspension test demonstrated longer accumulated time immobile for KO mice as compared WT mice (\(P\)-value <0.05). Borderline statistical significance was observed for male \(\text{Csmd1}\) KO mice as compared to WT mice (\(P\)-value = 0.1). doi:10.1371/journal.pone.0079501.g006
Csmd1 knockout mice were bred on a mixed background of 129SvEvBrd:C57BL/6NTac and genotyped according to the provided protocol (Taconic, Denmark). We used a high number of mice in the breeding strategy and tested a high number of littermate offspring, to control for potential effects mediated by maternal and paternal effects. The mice were in general healthy and fertile with 8–10 pups per litter, but showed signs of deregulation of specific neurological functions (See Supporting Information file S1).

RNA-seq and Bioinformatics Analyses
RNA was extracted from adult mouse cortex by RNeasy Mini Kit (Qiagen) and genotyped according to the provided protocol (Taconic, Denmark). We used a high number of mice in the breeding strategy and tested a high number of littermate offspring, to control for potential effects mediated by maternal and paternal effects. The mice were in general healthy and fertile with 8–10 pups per litter, but showed signs of deregulation of specific neurological functions (See Supporting Information file S1).

Behavioral Testing
Neuropsychological behaviors were examined in a selection of standard tests using 23 Csmd1 KO mice (11 males and 12 female) and 24 WT mice (12 males and 12 females). Mice were housed individually 2 weeks before start of the first test. Tests were performed in the following sequential order, starting at the age of 10 weeks: 1st week: open field (OF); 2nd week: novel object recognition memory in Csmd1 KO mice.
recognition test (NORT), 3rd week: startle reflex and prepulse inhibition test (PPI), 4th week: tail suspension test (TST), 5-6th week: comprehensive cage monitoring system (CCMS). Testing was performed in the first phase of the light cycle between 6 AM and 12 PM, and standard acclimation procedures were applied for each behavioral test. The experiment was recorded and monitored by Viewpoint where applicable. Elevated plus maze test (EPM) was performed on a separate colony of female littermate mice, obtained from a heterozygous breeding strategy (C57/ KO and 13 WT mice) and was tested for a period of 6 minutes in the EPM arena at 12 weeks of age. A brief description of behavioral tests can be found in Supporting Information file S1.

Statistical Analysis
Statistical significance was evaluated with unpaired t-test or 2-way analysis of variance (ANOVA) as applicable. Significance threshold was set to $p<0.05$. Data are shown as mean ± SEM in figures or text. Behavioral data were analyzed with GraphPad Prism (San Diego, California, USA), and statistical significance for expression analyses was examined in Excel (Microsoft Corporation).

Supporting Information
File S1 Supporting information. (DOCX)

Author Contributions
Conceived and designed the experiments: BH VMS. Performed the experiments: BH KM. RH MN SMR SS. Analyzed the data: BH CN. Contributed reagents/materials/analysis tools: BH VMS. Wrote the paper: BH.

References
1. Dernovšek MZ, Šprah L (2009) Comorbid anxiety in patients with psychosis. Psychiatr Danub 21 Suppl 1: 43–50.
2. Borns AR (2006) Prenatal infection as a risk factor for schizophrenia. Schizophren Bull 32: 200–202.
3. Sullivan PF, Daly MJ, O’Donovan M (2012) Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 13: 537–551.
4. Lichtenstein P, Yip BH, Bjo¨rk C, Pawitan Y, Cannon TD, et al. (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373: 234–239.
5. Hâvik B, Rokke H, Døye G, Stavrum AK, Bramham CR, et al. (2012) The formation of the glutamatergic synapse in the dentate gyrus of adult behaving rats: induction of immunity-linked genes. Neuroscience 140: 925–936.
6. Hâvik B, Le Hellard S, Kvamsch M, Lybeck H, Djurovic S, et al. (2011) The complement control-related genes CSM1D and CSM2D Associate to Schizophrenia. Biological Psychiatry 70: 35–42.
7. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (2011) Genome-wide association study identifies five new schizophrenia loci. Nature Genetics 43: 969–976.
8. Kraus DM, Elliott GS, Chute H, Horan T, Penninghen KH, et al. (2006) CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol 176: 4419–4430.
9. Escudero-Esparza A, Cháslávská N, Kurbasic E (2013) The novel complement inhibitor human CUB and Susli multiple domains 1 (CSM1D) protein promotes factor I-mediated degradation of C3b and C3b and inhibits the membrane attack complex assembly. FASEB J. doi: 10.1096/fj.13-230706.
10. Robinson EG, Bademian MCM, Langfeld CDC, Borns AR, Craney JPM, et al. (2012) Brief report: enrichment of associations in genes with fibrosis, apoptosis, and innate immunity functions with cardiac manifestations of neonatal lupus. Arthritis Rheum 64: 400–406.
11. Schaefer DP, Lehrman EK, Kustanoff AG, Koyama R, Marldiny AR, et al. (2012) Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 74: 691–705.
12. Schaefer DP, Lehrman EK, Stevens B (2013) The “quad-partite” synapse: Microglia-synapse interactions in the developing and mature CNS. Glia 61: 24–36.
13. Sullivan PF, de Geus EJC, Willemse G, James MR, Smit BH, et al. (2008) Genome-wide association for major depressive disorder: a possible role for the presynaptic protein Piccolo. Mol Psychiatry 14: 559–575.
14. Sklar P, Smoller JW, Fan J, Ferreira SB, Perl sized by Single-Cell Transcript Map of the 8p23 Putative Tumor Suppressor Region. Genomics 75: 1350–1355.
15. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26: 137–141.
16. Williams KW, Elmquist JK (2012) From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Rev Endocr Metab Disord 12: 127–140.
17. Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M (2012) Ablates normal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophrenia Bulletin 38: 280–284.
18. Feron J, Skrede S, Vik-Mo AO, Jasmis G, Le Hellard S, et al. (2011) Lipogenic effects of psychotropic drugs: focus on the SREBP system. Front Biosci 16: 49–60.
19. Sun PC, Uppaluri R, Schmidt AP, Pashia ME, Quant EC, et al. (2001) Transcript Map of the lip23 Putative Tumor Suppressor Region. Genomics 75: 17–25.
20. Kirkpatridge MD, Barlow PN (2001) Structure and flexibility of the multiple proteins that regulate complement activation. Immuno Rev 180: 146–161.
39. Wagner E, Frank MM (2009) Therapeutic potential of complement modulation. Nat Rev Drug Discov 9: 43–56.
40. Shatz CJ (2009) MHC class I: an unexpected role in neuronal plasticity. Neuron 64: 40–45.
41. Schafer DP, Stevens B (2010) Synapse elimination during development and disease: immune molecules take center stage. Biochem Soc Trans 38: 476–481.
42. Datwani A, McConnell MJ, Kanold PO, Kanold PO, Micheva KD, et al. (2009) Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity. Neuron 64: 463–470.
43. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, et al. (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164–1178.
44. Friddle CJ, Absin A, Ramirez-Solis R, Richter LJ, Buxton EC, et al. (2003) High-throughput mouse knockouts provide a functional analysis of the genome. Cold Spring Harbor Symp Quant Biol 68: 311–315.
45. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105–1111.
46. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511–515.
47. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106.